A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

Inclusion Criteria:

* Participants with locally advanced or metastatic solid tumors who have received three or less prior lines of systemic chemotherapy
* Participants must have relapsed or had progressive disease following standard of care treatment with chemotherapy prior to enrollment, or intolerant to prior standard of care treatment with chemotherapy
* Normal cardiac conduction and function as documented on a 12-lead electrocardiogram
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
* Adequate organ function as evidenced by laboratory tests
* Able to receive dexamethasone or its equivalent
* Agrees to protocol-defined use of effective contraception

Exclusion Criteria:

* Participants treated with more than three prior chemotherapy regimens (including adjuvant therapy)
* Previous exposure to trabectedin
* Central nervous system (CNS) metastasis
* Known hypersensitivity to any of the components of the trabectedin intravenous formulation or dexamethasone
* Heart rhythm disturbances, unusual T wave and U wave (if present) morphology, blood pressure outside of normal range, a history of cardiac failure, myocardial infarction, or cardiomyopathy, or a history of additional risk factors for torsade de pointes (eg, heart failure, electrolyte abnormalities, family history of Long QT Syndrome)
* Participants who at screening are on medication that is known to prolong the QT interval or who is on CYP3A4 inhibitors or inducers